Invitrogen Launches System for Large Scale Protein Production

Invitrogen Corporation has introduced the FreeStyle™ MAX System-designed for large scale protein production in the preferred cell lines for a number of bio-pharmaceutical and pre-clinical applications.

"Our first try with the new system gave over ten-fold higher yields of the same recombinant protein from the same vectors," said Dr. David Wilson, Vice-President, Therapeutic Antibody Development at EvoGeniX, one of the early evaluators of the FreeStyle™ MAX System.

The FreeStyle™ MAX System is a protein production technology developed for large-scale generation of post-translationally modified, functional proteins in Chinese Hamster Ovary (CHO) and HEK-293 suspension cell cultures.

It is the commercially available large-scale transient transfection system optimized with CHO suspension culture-the preferred cell line for pre-clinical testing and producing FDA-approved protein for therapeutic applications. 

"We listened to our customers and matched our product development focus to their requirements for protein production in their applications," concluded Mark Gardner, Invitrogen’s Vice President of Molecular Biology Essentials. 

"With the introduction of FreeStyle™ MAX, we have delivered a new system of technologies to meet these needs."